Clinical trial · Interventional
uPAR PET/CT in Radium-223-dichloride Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
NCT02964988CI-TRIAL-00041141terminatedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Recruitment issues and interim results
Summary
Brief summary (as posted)
The purpose of this study is to investigate the applicability of urokinase plasminogen activator receptor (uPAR) Positron Emission Tomography (PET) / CT molecular imaging in patients with metastatic castration-resistant prostate cancer (mCRPC)
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bone Metastases | — | UNRESOLVED | — |
| Prostate Cancer Metastatic | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Injection of PET tracer 68Ga-NOTA-AE105 | Drug | — | UNRESOLVED |
| PET/CT | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- uPAR PET/CT
- description
- Injection of 68Ga-NOTA-AE105 followed by PET/CT scan. Administration will be performed twice in approximately 8 weeks.
- interventionNames
- Drug: Injection of PET tracer 68Ga-NOTA-AE105
- Device: PET/CT
Primary outcomes (2)
- measure
- uPAR PET/CT imaging
- timeFrame
- 1 hour post injection
- description
- Standard uptake values (SUVs) of 68Ga-NOTA-AE105 evaluated on uPAR-PET/CT scan performed within 1 hour following injection of 68Ga-NOTA-AE105
- measure
- Change in uPAR PET/CT after two cycles of Radium-223
- timeFrame
- 8 weeks
- description
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Metastatic castration resistant prostate cancer * Approved to receive Radium-223 therapy * Written and oral consent Exclusion Criteria: * Lack of communication skills * Other known malignant disease * Known allergy towards IMP * Severe claustrophobia * If a participant exhibits allergic reaction i the IMP, the participant will be excluded from further participation in the study
References
Publications (0)
Data not yet available
No reference posted for this study.